Biotechnology innovation and new product development underpin some of the most impactful public health interventions in recent generations. I have been fortunate to contribute to some of them with my work on the technologies that shifted testing of the nations blood supply to molecular testing, as well as, first-in-class genetic engineering programs for food, health and environment.

  • Genetic, genome, and molecular engineering technologies for food and protein production
  • Medical diagnostics, food safety testing, and environmental threat detection
  • Genetic, genome, and molecular engineering of human and animal therapeutics, medicines, and vaccines
  • Molecular epidemiology, epidemic intelligence, environmental and public health interventions

Currently advancing and raising to further execute on R&D projects: (redirect to
  • Quantitative serological SARS-CoV-2 (COVID) assay for protective neutralizing antibodies
  • Protein production of animal-free growth factors for cultivated meats with algal expression systems
  • Engineering SARS-CoV-2 sewer surveillance systems and environmental testing platforms

Executed on multiple first-in-class advanced detection programs yielding FDA cleared CBER regulated blood screening and CDRH regulated medical diagnostics, including:

Participated in technology diligence to support acquisition or internal development and deployment of novel biotechnology platforms and first-in-class products reviewed by FDA, USDA, EPA and US FWS regulators:
  • AquaBounty genetically engineered fish, first GE food animal approved for human consumption (salmon)
  • Oxitec genetically engineered insects to fight infectious disease and agricultural pests ($160M acquisition)
  • ViaGen cloning for food and companion animals, as well as endangered species
  • Trans Ova Genetics bovine reproductive technologies ($110M acquisition)
  • Okanagan Specialty Fruits genetically engineered non-browning apples and other fruits ($41M acquisition)
  • EnviroFlight alternative protein feed nutrition using insect larvae
  • GenVec human and animal molecular vaccine platform
  • Engineered cell therapy platforms
  • ActoGeniX (ActoBiotics™) engineered microbial human and food animal medicinal platform ($60M acquisition)
  • Genomatix proprietary software for promoter design for genetic and genomic engineering
  • ILH, formerly Codexis, protein production facility in Hungary
  • Intrexon’s UltraVector® platform for protein engineering and gene switches for control of protein production [microbes, plants, animals, humans]
  • Intrexon’s pioneering of gene-edited environmental clean-up systems for emerging contaminants of concern [e.g., 1,4-dioxane]

Additional Highlights and Details
  • Expertise developing molecular diagnostics, immunoassays, and microarrays for chronic and infectious diseases (Scripps Research, Gen-Probe, Nanogen, Exonhit, Intrexon)
  • Advanced numerous biodefense and biosecurity medical countermeasure technologies: diagnostics and detection systems, vaccines, therapeutics (Gen-Probe, Nanogen, Intrexon)
  • Managed technology portfolio including DNA molecular vaccines, diagnostics, and cell and gene therapies for publicly traded multi-national conglomerate (Intrexon)

For over two decades, I have been advancing biotechnologies and gaining expertise on the frontlines of numerous medical, environmental, and public health interventions including:
  • Molecular testing for safety of the U.S. blood supply: HIV, HCV, West Nile virus (Gen-Probe > Grifols)
  • Launch of first combined Chlamydia and Gonorrhea Aptima molecular tests, eliminating need for male genital swabbing using male/female urine specimens (Gen-Probe > Hologic)
  • Respiratory infectious diseases diagnostics panel (Nanogen)
  • Alzheimer's disease microarray molecular diagnostic (Exonhit)
  • Cancer screening molecular profiling platforms (Intrexon)
  • Biodefense and biothreat mobile detection systems for intelligence community (Nanogen / Vectrant)
  • Translation of FDA cleared APTIMA CT/GC nucleic acid test to APTIMA ASR Rapid Response Molecular Detection Platform for biothreats (Gen-Probe > Hologic)
  • Infectious disease testing and vector control interventions for mosquito-borne diseases (Gen-Probe, St. Gabriel’s Hospital - Malawi, Intrexon, Oxitec)
  • Invasive species population control approaches (Intrexon, Oxitec)
  • Pioneering development of gene-edited environmental clean-up systems for emerging contaminants of concern (COCs) [i.e. 1,4-dioxane] (Intrexon)
  • Cloning of animals for food, companions, and conservation programs (Intrexon, ViaGen)
  • First FDA approved bioengineered food animal (salmon) for human consumption (Intrexon, AquaBounty)
  • Biological applications for consumer products (Intrexon)